Cargando…

Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain

OBJECTIVE: HIV-associated neurocognitive deficits remain a challenge despite suppressive combined antiretroviral therapy. Given the association between HIV-induced central nervous system (CNS) disease and replication of HIV in immune-activated macrophages, CCR5 antagonists may attenuate CNS disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Kelly, Kathleen M., Beck, Sarah E., Pate, Kelly A. Metcalf, Queen, Suzanne E., Dorsey, Jamie L., Adams, Robert J., Avery, Lindsay B., Hubbard, Walter, Tarwater, Patrick M., Mankowski, Joseph L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235167/
https://www.ncbi.nlm.nih.gov/pubmed/24051706
http://dx.doi.org/10.1097/QAD.0000000000000074
_version_ 1782344978405523456
author Kelly, Kathleen M.
Beck, Sarah E.
Pate, Kelly A. Metcalf
Queen, Suzanne E.
Dorsey, Jamie L.
Adams, Robert J.
Avery, Lindsay B.
Hubbard, Walter
Tarwater, Patrick M.
Mankowski, Joseph L.
author_facet Kelly, Kathleen M.
Beck, Sarah E.
Pate, Kelly A. Metcalf
Queen, Suzanne E.
Dorsey, Jamie L.
Adams, Robert J.
Avery, Lindsay B.
Hubbard, Walter
Tarwater, Patrick M.
Mankowski, Joseph L.
author_sort Kelly, Kathleen M.
collection PubMed
description OBJECTIVE: HIV-associated neurocognitive deficits remain a challenge despite suppressive combined antiretroviral therapy. Given the association between HIV-induced central nervous system (CNS) disease and replication of HIV in immune-activated macrophages, CCR5 antagonists may attenuate CNS disease by modulating inflammatory signaling and by limiting viral replication. DESIGN: To establish whether initiating CCR5 inhibition during early infection altered CNS disease progression, outcomes were compared between simian immunodeficiency virus (SIV)-infected macaques treated with maraviroc (MVC) versus untreated SIV-infected macaques. METHODS: Six SIV-infected rhesus macaques were treated with MVC monotherapy for 5 months beginning 24 days postinoculation; 22 SIV-infected animals served as untreated controls. SIV RNA levels in plasma, cerobrospinal fluid, and brain, and CNS expression of TNFα and CCL2 were measured by qRT-PCR. Immunostaining for CD68 and amyloid precursor protein in the brain was measured by image analysis. Plasma sCD163 was measured by ELISA. RESULTS: SIV RNA and proviral DNA levels in brain were markedly lower with MVC treatment, demonstrating CCR5 inhibition reduces CNS replication of SIV and may reduce the CNS latent viral reservoir. MVC treatment also lowered monocyte and macrophage activation, represented by CNS CD68 immunostaining and plasma sCD163 levels, and reduced both TNFα and CCL2 RNA expression in brain. Treatment also reduced axonal amyloid precursor protein immunostaining to levels present in uninfected animals, consistent with neuroprotection. CONCLUSION: CCR5 inhibitors may prevent neurologic disorders in HIV-infected individuals by reducing inflammation and by limiting viral replication in the brain. Furthermore, CCR5 inhibitors may reduce the latent viral reservoir in the CNS. Adding CCR5 inhibitors to combined antiretroviral regimens may offer multiple neuroprotective benefits.
format Online
Article
Text
id pubmed-4235167
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-42351672014-11-18 Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain Kelly, Kathleen M. Beck, Sarah E. Pate, Kelly A. Metcalf Queen, Suzanne E. Dorsey, Jamie L. Adams, Robert J. Avery, Lindsay B. Hubbard, Walter Tarwater, Patrick M. Mankowski, Joseph L. AIDS Fast Track OBJECTIVE: HIV-associated neurocognitive deficits remain a challenge despite suppressive combined antiretroviral therapy. Given the association between HIV-induced central nervous system (CNS) disease and replication of HIV in immune-activated macrophages, CCR5 antagonists may attenuate CNS disease by modulating inflammatory signaling and by limiting viral replication. DESIGN: To establish whether initiating CCR5 inhibition during early infection altered CNS disease progression, outcomes were compared between simian immunodeficiency virus (SIV)-infected macaques treated with maraviroc (MVC) versus untreated SIV-infected macaques. METHODS: Six SIV-infected rhesus macaques were treated with MVC monotherapy for 5 months beginning 24 days postinoculation; 22 SIV-infected animals served as untreated controls. SIV RNA levels in plasma, cerobrospinal fluid, and brain, and CNS expression of TNFα and CCL2 were measured by qRT-PCR. Immunostaining for CD68 and amyloid precursor protein in the brain was measured by image analysis. Plasma sCD163 was measured by ELISA. RESULTS: SIV RNA and proviral DNA levels in brain were markedly lower with MVC treatment, demonstrating CCR5 inhibition reduces CNS replication of SIV and may reduce the CNS latent viral reservoir. MVC treatment also lowered monocyte and macrophage activation, represented by CNS CD68 immunostaining and plasma sCD163 levels, and reduced both TNFα and CCL2 RNA expression in brain. Treatment also reduced axonal amyloid precursor protein immunostaining to levels present in uninfected animals, consistent with neuroprotection. CONCLUSION: CCR5 inhibitors may prevent neurologic disorders in HIV-infected individuals by reducing inflammation and by limiting viral replication in the brain. Furthermore, CCR5 inhibitors may reduce the latent viral reservoir in the CNS. Adding CCR5 inhibitors to combined antiretroviral regimens may offer multiple neuroprotective benefits. Lippincott Williams & Wilkins 2013-11-28 2013-11-18 /pmc/articles/PMC4235167/ /pubmed/24051706 http://dx.doi.org/10.1097/QAD.0000000000000074 Text en © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins http://creativecommons.org/licenses/by-nc-nd/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.
spellingShingle Fast Track
Kelly, Kathleen M.
Beck, Sarah E.
Pate, Kelly A. Metcalf
Queen, Suzanne E.
Dorsey, Jamie L.
Adams, Robert J.
Avery, Lindsay B.
Hubbard, Walter
Tarwater, Patrick M.
Mankowski, Joseph L.
Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain
title Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain
title_full Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain
title_fullStr Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain
title_full_unstemmed Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain
title_short Neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent SIV in the brain
title_sort neuroprotective maraviroc monotherapy in simian immunodeficiency virus-infected macaques: reduced replicating and latent siv in the brain
topic Fast Track
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4235167/
https://www.ncbi.nlm.nih.gov/pubmed/24051706
http://dx.doi.org/10.1097/QAD.0000000000000074
work_keys_str_mv AT kellykathleenm neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT becksarahe neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT patekellyametcalf neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT queensuzannee neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT dorseyjamiel neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT adamsrobertj neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT averylindsayb neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT hubbardwalter neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT tarwaterpatrickm neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain
AT mankowskijosephl neuroprotectivemaravirocmonotherapyinsimianimmunodeficiencyvirusinfectedmacaquesreducedreplicatingandlatentsivinthebrain